Therapeutic strategies in preclinical stages of rheumatoid arthritis.
Nils SchulzUwe LangePhilipp KlemmPublished in: Polish archives of internal medicine (2024)
Modern therapies and treatment algorithms like treat to target have significantly improved outcomes in rheumatoid arthritis over the past decades. Moreover, the "window of opportunity" concept has led to early diagnosis and treatment with improved outcomes. Nevertheless, individuals are still impacted by progressive disease courses, which also inflict a socioeconomic burden. Therefore, novel concepts of treatment are investigated. One of those is the concept of primary prevention: treating patients at risk for developing rheumatoid arthritis for a short period of time so they do not develop the full disease. The initiation of treatment in preclinical phases of rheumatoid arthritis is expected to delay, halt or even prevent the disease onset or progression in the long term. This review summarizes the concept itself, current studies with their therapeutic algorithm and findings and provides a critical evaluation of pharmacological therapy in the preclinical stages of rheumatoid arthritis.
Keyphrases
- rheumatoid arthritis
- disease activity
- machine learning
- ankylosing spondylitis
- cell therapy
- stem cells
- ejection fraction
- newly diagnosed
- type diabetes
- end stage renal disease
- systemic lupus erythematosus
- mass spectrometry
- case control
- peritoneal dialysis
- patient reported outcomes
- neural network
- glycemic control
- high speed